Corrigendum 1

The authors would like to note the following amendment regarding their Review printed in a recent issue of Leukemia & Lymphoma, May 2009;50(5):694–702.

The Review is entitled:

Clinical challenges associated with bortezomib therapy in multiple myeloma and Wa1denströms Macroglobulinemia

JACOB P. LAUBACH, CONSTANTINE S. MITSIADES, ALDO M. ROCCARO, IRENE M. GHOBRIAL, KENNETH C. ANDERSON, & PAUL G. RICHARDSON

The Declaration of Interest statement should have detailed the following:

JACOB P. LAUBACH: Consultant or advisory role (Novartis)

CONSTANTINE S. MITSIADES: Consultant or advisory role (Millennium, Novartis, Bistol-Myers

Squibb, Merk and Co., Kosan, Pharmion)

IRENE M. GHOBRIAL: Speakers Bureau (Celgene, Millennium, Novartis), Research Support

(Celgene, Millennium)

KENNETH C. ANDERSON: Consultant or advisory role (Millennium, Celgene, Novartis), Research

Support (Celgene, Millennium) Speakers Bureau (Celgene, Millennium)

PAUL G. RICHARDSON: Consultant or advisory role (Millennium. Celgene), Speakers Bureau

(Millennium, Celgene)

Corrigendum 2

The authors would like to note the following amendment regarding the authorship of their Research article printed in a recent issue of Leukemia & Lymphoma, May 2009;50(5):816–828.

The article is entitled:

The Spt-Ada-Gcn5-acetyltransferase complex interaction motif of E2a is essential for a subset of transcriptional and oncogenic properties of E2a-Pbxl

JÜRGEN S. SCHEELE¹, MATEUSZ KOLANCZYK¹, MELANIE CANTERT¹, TOMASZ ZEMOJTEL¹, ANNETTE DORN¹, DAVID P. SYKES², DIETRICH C. C. MÖBEST¹, MARK P. KAMPS², DANIEL RÄPPLE¹, & MARLENA DUCHNIEWICZ¹

The authorship should have read as follows:

JÜRGEN S. SCHEELE¹, MATEUSZ KOLANCZYK¹, MELANIE GANTERT¹, TOMASZ ZEMOJTEL¹, ANNETTE DORN¹, DAVID P. SYKES², DIETRICH C. C. MÖBEST¹, MARK P. KAMPS², & DANIEL RÄPPLE¹